Search

Purpose: To compare the lesion sizes of macular neovascularization (MNV) imaged with spectral‐domain (SD) and swept‐source (SS) optical coherence tomography angiography (OCTA) as well as indocyanine green angiography (ICGA). Methods: In this prospective, observational case series, patients showing a secured diagnosis of MNV on ICGA or Fluorescein Angiography, were imaged by SD‐OCTA and SS‐OCTA on the same day. Lesion size was measured on 3 × 3‐mm2 and 6 × 6‐mm2 scans using the Maestro 2 SD‐OCTA (Topcon Corporation, Tokyo Japan) and the Triton SS‐OCTA device (Topcon Corporation, Tokyo Japan) and compared to ICGA (Spectralis HRA, Heidelberg, Germany). Results: Twenty eyes from 20 patients (11 females, 55%) were enrolled. The neovascularization area measured on 6 × 6‐mm2 SD‐OCTA was lower compared to that outlined on SS‐OCTA, however, not reaching statistical significance (p = 0.094). Regarding 3 × 3‐mm2 measurements, the median lesion sizes between the two OCTA devices were comparable (p = 0.492). Indocyanine green angiography depicted a larger lesion area than both OCTA devices, however, not reaching statistical significance. Conclusion: SD‐OCTA tends to show smaller areas of MNV extension than SS‐OCTA regarding 6 × 6 mm2 scans. The lesion size of MNV can be very well compared between the different devices, emphasizing the use of OCTA for monitoring neovascular area. Lesion measurements on SS‐OCTA correlate better with ICGA than SD‐OCTA. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate treatment of macular oedema due to branch retinal vein occlusion (BRVO) with intravitreal triamcinolone acetonide. Methods: In a prospective case series, nine patients with macular oedema due to BRVO received an intravitreal injection of 4 mg triamcinolone acetonide. Examination included best-corrected visual acuity (BCVA) for distance and reading, intraocular pressure (IOP) measurement, fluorescein angiography and high resolution imaging by optical coherence tomography, preoperatively and at 1 week, 1 month, 3 and 6 months postoperatively. Results: Preoperative mean BCVAs were 1.3 ± 0.8 for distance vision, and 1.1 ± 0.3 for reading acuity, respectively. A significant improvement in reading acuity was observed until 1 month (0.7 ± 0.4, p = 0.02). No significant reduction in mean macular thickness was observed. Conclusions: Intravitreal injection of triamcinolone acetonide led to a significant improvement in mean VA in patients with macular oedema due to BRVO. However, the significant effect was not permanent and persisted for only 1 month. [ABSTRACT FROM AUTHOR]

To evaluate treatment of macular oedema due to central retinal vein occlusion (CRVO) with intravitreal triamcinolone acetonide.In a prospective case series, 13 patients with macular oedema due to non-ischaemic CRVO received an intravitreal injection of 4 mg triamcinolone acetonide. Examination included assessment of best corrected visual acuity (BCVA) for distance and reading, measurement of intraocular pressure (IOP), fluorescein angiography and high resolution imaging by optical coherence tomography, preoperatively and 1 week, 1 month, 3, 6 and 9 months postoperatively.Preoperative mean BCVA was 0.9 ± 0.4 for distance vision and 1.0 ± 0.3 for reading acuity, respectively. A significant improvement in distance VA (0.5 ± 0.3, p < 0.001) and reading acuity (0.7 ± 0.3, p = 0.03) was observed until 3 months and 6 months, respectively. Mean macular thickness was significantly reduced until 9 months postoperatively.Intravitreal injection of triamcinolone acetonide led to a significant improvement in mean VA in patients with macular oedema due to CRVO. However, the significant effect was not permanent and persisted for a maximum of 6 months. [ABSTRACT FROM AUTHOR]

In uveitis patients therapy usually depends on the aetiology of the disease and a correct diagnosis is therefore important. A diagnostic vitrectomy with laboratory workup of vitreous specimens can improve the likelyhood of diagnosis. In therapeutiv vitrectomy, removing infiltrated vitreous helps in diagnosis by restoring fundus view and removes potentially harmful inflammatory and infectious material from the eye. Visual acuity has been reported to improve in 70%‐90% of cases depending on aetiology. Secondary retinal problems such as Epiretinal membranes with macular traction, macular holes or retinal breaks and detachment can be successfully treated. Additional treatment with intravitreal steroids can be considered. Combining modern microincisional vitrectomy surgery with phacoemulsification is a safe option. [ABSTRACT FROM AUTHOR]

To assess satisfaction with photocoagulation treatment in diabetes patients and to investigate how it relates to patient-related characteristics and patients' visual ability. Further, to observe the interaction between physician and patient and suggest ways to improve the patient−provider relationship and, thereby, treatment satisfaction.This open longitudinal study included 123 diabetes patients undergoing first photocoagulation treatment for diabetic maculopathy or proliferative retinopathy. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was completed by all patients. Communication, scheduling and adherence scores were defined for each physician−patient pair. Outcome measures were: the patient's overall satisfaction with laser treatment; the patient's degree of satisfaction in relation to visual results; communication, scheduling and adherence scores, and visual acuity results.The level of satisfaction after initial photocoagulation treatment was high; 46.4% of patients with proliferative retinopathy and 53.1% with maculopathy scored 31 or higher. Although 69.5% of all patients reported that their expectations of treatment corresponded to their final 9-month visual results, only 8.7% of these patients reported an improvement in visual acuity after 9 months. The number of unwanted actions performed by the patients during treatment were significantly related to the number of unclear instructions given by the physician (Fisher's exact testP < 0.01).A high level of satisfaction was observed, despite the minimal improvements in visual acuity. Attempts to further improve patient satisfaction might focus on improved education of patients on the possible benefits of laser treatment, greater care in communicating information during treatment, additional nursing support, and additional clerical time to communicate with patients before each appointment. [ABSTRACT FROM AUTHOR]